ArticleFrontiers in microbiology2022
Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Genetic Diversity of Newcastle Disease Virus and Its Implications for Vaccine Development.Veterinary sciences · 2025Review
- Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development.Plants (Basel, Switzerland) · 2024Review
- Wuhan Sequence-Based Recombinant Antigens Expressed inInternational journal of molecular sciences · 2024Article
- Novel Universal Recombinant Rotavirus A Vaccine Candidate: Evaluation of Immunological Properties.Viruses · 2024Article
- Review
- Dataset on safety and protective efficacy studies of COVID-19 vaccine candidates based on structurally modified plant virus in female hamsters.Data in brief · 2023Article
- Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress.International journal of molecular sciences · 2023Review
- Structurally Modified Plant Viruses and Bacteriophages with Helical Structure. Properties and Applications.Biochemistry. Biokhimiia · 2022Review
- Designing StablePharmaceutics · 2022Article
- New formulation of a recombinant anthrax vaccine stabilised with structurally modified plant viruses.Frontiers in microbiology · 2022Article
- Plant Viruses: New Opportunities under the Pandemic.Herald of the Russian Academy of Sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recombinant vaccine candidate has been developed based on the major coronaviruses' antigen (S protein) fragments and a novel adjuvant-spherical particles (SPs) formed during tobacco mosaic virus thermal remodeling. The receptor-binding domain and the highly conserved antigenic fragments of the S2 protein subunit were chosen for the design of recombinant coronavirus antigens. The set of three antigens (Co1, CoF, and PE) was developed and used to create a vaccine candidate composed of antigens and SPs (SPs + 3AG). Recognition of SPs + 3AG compositions by commercially available antibodies against spike proteins of SARS-CoV and SARS-CoV-2 was confirmed. The immunogenicity testing of these compositions in a mouse model showed that SPs improved immune response to the CoF and PE antigens. Total IgG titers against both proteins were 9-16 times higher than those to SPs. Neutralizing activity against SARS-CoV-2 in serum samples collected from hamsters immunized with the SPs + 3AG was demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.